[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"freezing-of-gait\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:freezing-of-gait":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,51,81,110,136,159,183,205,231,254,279,307],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100461756","use-of-ceregate-therapy-for-freezing-of-gait-in-pd-100461756",false,"NCT05292794","Use of CereGate Therapy for Freezing of Gait in PD","A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed With Parkinson's Disease","Inclusion Criteria:\n\n1. Participant has an implanted STN-DBS system with Boston Scientific Gevia™ or Genus™ R16 IPG connected to any brand lead or extension that have been approved by the FDA to be used with Gevia or Genus IPGs.\n2. Participant is receiving treatment with carbidopa\u002Flevodopa, and\u002For with a dopamine agonist at the optimal doses as determined by a movement disorders neurologist.\n3. DBS optimized with documented improvement in motor signs (UPDRSIII) from DBS\n\nExclusion Criteria:\n\n1. Participant is unable to understand the study requirements and the treatment procedures, or unwilling \u002F unable to provide written informed consent before any study-specific tests or procedures are performed.\n2. Participant is unwilling or unable to comply with visit schedule and study related procedures.\n3. Participant's medication regimen has not been stable for at least 28 days prior to CG initiation.\n4. Participant's DBS stimulation settings have not been stable for at least 28 days prior to CG initiation.\n5. Participant is less than 21 years of age or older than 80 years of age.\n6. Participant is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception as determined by the study investigator.\n7. Participant has a terminal illness with life expectancy of \\\u003C 1 year.\n8. Participant has history of recurrent or unprovoked seizures.\n9. Participant currently diagnosed with drug or alcohol abuse, per DSM-5 criteria.\n10. Participant is in a very advanced stage of Parkinson's disease defined as: (i) Stage 5 as classified by the Hoehn and Yahr scale on medication and DBS (non-ambulatory) or (ii) participant requires an assistive device to perform the TBC OFF-meds \u002FON-DBS at the time of enrollment.\n11. Participant has a condition that makes walking difficult or could interfere with the study procedures or confound the evaluation of the study data, including musculoskeletal issues, peripheral neuropathies, hip\u002Fknee prostheses, or any visual or anatomical abnormality that affects their walking.\n12. Participant has disabling dyskinesias.\n13. Participant has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Items 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSRS).\n14. Participant, at the time of enrollment, fails the subthalamic nucleus (STN) stimulation challenge test (subject must perceive distinct bilateral sensations).\n15. Participant has less than 8% arrhythmicity as measured in the Turning and Barrier Course Figures of 8 (TBC-F8) pre-CG therapy (ON Medications\u002FON DBS \u002FOFF CG).","ALL","21 Years","80 Years",{"count":20,"type":21},41,"ESTIMATED","INTERVENTIONAL",[24],"NA","A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.",[27,28,29],"Parkinson Disease","Freezing of Gait","Deep Brain Stimulation",[27,31,28,32,33,34,35,36,37],"Parkinson's Disease","Freezing of Gait Symptoms in Parkinson Disease","Gait Disorders","Gait Disorders, Neurologic","Gait Disorder, Sensorimotor","Motor Disorder","Gait Impairment","RECRUITING","2026-05-25",{"date":41,"type":42},"2026-05-28","ACTUAL",{"date":44,"type":42},"2022-04-18",{"date":46,"type":21},"2027-07",{"name":48,"class":49},"CereGate Inc.","INDUSTRY",7,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100637518","aid-fog-artificial-intelligence-driven-freezing-of-gait-detection-in-the-home-100637518","NCT07580612","AID-FOG: Artificial Intelligence-Driven Freezing of Gait Detection in the Home","Artificial Intelligence-Driven Freezing Of Gait Detection in the Home: Investigating How Free-living Activities Affect the Algorithm","AID-FOG","Inclusion Criteria:\n\nFor all participants\n\n* Voluntary written informed consent of the participant has been obtained prior to any study-related procedures, except the non-recorded pre-screening questions;\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF);\n* Person is cognitively able to follow and understand instructions and provide voluntary written informed consent;\n* Person is able to walk for short distances (± 10 meters) independently, with- or without use of a walking aid;\n* Person does not live in a temporary or permanent care facility.\n\nFor participants with PD:\n\n* Clinical diagnosis of Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;\n* Person self-reports to experience daily FOG (for recruitment of freezers only);\n* Person is willing to temporarily delay the morning anti-Parkinsonian medication during the standardized assessment visit.\n\nExclusion criteria:\n\n* Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \\>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait;\n* Participant self-reports daily falls;\n* Participation in another interventional study, with or without an investigational medicinal product (IMP) or device (IMD)",true,"18 Years",{"count":62,"type":21},126,"OBSERVATIONAL","Freezing of gait (FOG) is a debilitating symptom of Parkinson's disease increases the risk of falling. Despite being a common symptom, it is still difficult to evaluate freezing of gait quickly and accurately. Currently, the gold-standard method to determine the severity of FOG is a manual analysis of video footage by an experienced assessor, collected during standardized FOG-provoking walking tests. Because this is a very time-intensive process, where different assessors sometimes obtain different results, our team at KU Leuven have developed an artificial-intelligent (AI) algorithm trained to identify FOG episodes based on wearable inertial measurement unit (IMU) sensor data. The AI algorithm has already undergone initial validation during laboratory testing, yielding promising results. The aim of this study is to investigate whether the AI algorithm can accurately detect FOG episodes in a less controlled environment, namely the home environment. In a second phase, the investigators will also use the collected data to improve the AI algorithm for automated FOG detection in the home. Finally, the investigators want to explore whether the AI algorithm can detect FOG in real-time.",[66,28,67,68,69],"Parkinson Disease, Idiopathic","Validation","Wearable Sensors","Artifical Intelligence","2026-05-05",{"date":72,"type":42},"2026-05-12",{"date":74,"type":42},"2025-09-22",{"date":76,"type":21},"2027-06",{"name":78,"class":79},"KU Leuven","OTHER",3,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":92,"studyType":63,"phases":4,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100622622","etiology-phenotype-outcome-pathway-study-on-freezing-of-gait-fog-100622622","NCT07386015","Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","FREEZE-Path Cohort: Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","Inclusion Criteria:\n\n1. Age 30-85 years\n2. Presence of freezing of gait or non-freezing gait or balance impairment\n3. Diagnosis of Parkinson's disease or related parkinsonian disorders according to established international criteria (including PD, PSP, MSA, DLB, CBD, vascular parkinsonism, or idiopathic normal pressure hydrocephalus)\n4. Ability to complete gait and balance assessment tasks independently or with assistance\n5. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe dementia (Mini-Mental State Examination score \\\u003C 10)\n2. Severe psychiatric disorders interfering with study participation\n3. Severe cardiopulmonary, musculoskeletal, or other medical conditions significantly affecting gait safety\n4. Stroke, fracture, or other major medical events within the past 3 months\n5. Inability to comply with follow-up procedures\n6. Refusal of video or speech data collection","30 Years","85 Years",{"count":91,"type":21},700,"36 Months","This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.",[28,31,95,96,97],"Parkinsonism","Vascular Parkinsonism","Idiopathic Normal Pressure Hydrocephalus (INPH)",[28,31,99],"parkinsonism","2026-03-08",{"date":102,"type":42},"2026-03-10",{"date":104,"type":42},"2026-02-28",{"date":106,"type":21},"2030-11-30",{"name":108,"class":79},"Tianjin Huanhu Hospital",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":109},"100581276","percept-transitions-in-fog-and-pd-100581276","NCT06848205","Percept Transitions in FOG and PD","Basal Ganglia Contributions to Transitions in Freezing of Gait and Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic PD.\n* Age 21-75 (see Inclusion of Individuals across the Lifespan for justification of age range).\n* Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters.\n* Implanted Medtronic Percept TM Device.\n* At least 3 months since the initial activation of the neurostimulator.\n* Undervalued, under-represented, or disenfranchised social group may be included.\n* Active members of the military (service members), DoD personnel (including civilian employees) may be included.\n* Individual or group that is disadvantaged in the distribution of social goods and services such as income, housing, or healthcare may be included.\n\nExclusion Criteria:\n\n* Meet criteria for dementia with Lewy bodies, Multiple Systems Atrophy, Alzheimer's disease, or other neurodegenerative disorder.\n* History of seizures or other significant neurological disorders that may affect participation or performance in the study.\n* History of musculoskeletal disorders that significantly affect walking or movement of limb(s) that would affect the participation in the experimental task (Participants will be excluded from that task, but may participate in other tasks, for example, may be excluded from Experiment 1 if the disorder affects walking, but may still participate in Experiment 3).\n* History of muscular conditions of the neck and back, including whiplash that would affect walking experiments.\n* History of visual and\u002For vestibular conditions that may affect participation or performance in the study.\n* Reduced capacity to consent. This will be assessed using a 2-stage process. Initially, participants will be tested using the University of California, San Diego, Brief Assessment of Capacity to Consent (UBACC). If concerns are raised from the UBACC test, the individual will be further tested using the MacArthur Competency Assessment Tool.\n* Pregnant people.\n* Post-operative complications or adverse effects (e.g. ON stimulation dystonia) that affect patient safety or confound the experiment.","75 Years",{"count":119,"type":21},36,[24],"The purpose of this research is to examine the possible causes and signs of freezing of gait (FOG) secondary to Parkinson's disease (PD). To achieve this, the study will use the novel (on-label and FDA-approved) local field potential (LFP) measuring capability of the Medtronic Percept™ deep brain stimulation (DBS) system to compare oscillatory activity in people who have Parkinson's disease, with and without freezing of gait (FOG). This will be conducted as three separate experiments, participants may volunteer for one or more experiments:\n\nExperiment 1: The first experiment will compare LFPs during gait initiation with and without a cue, in people with (PD+FOG) and without FOG (PD-FOG).\n\nExperiment 2: The second experiment will compare LFPs during the successful movement transitions vs. freezing-events during a FOG provocation course in people with FOG.\n\nExperiment 3: The third experiment will compare LFPs during rapid alternating movements of the wrist and\u002For foot, in people with and without FOG",[28,27],[124,125,28,126],"FOG","PD","Parkinson disease","2026-03-02",{"date":129,"type":42},"2026-03-03",{"date":131,"type":42},"2026-02-26",{"date":133,"type":21},"2029-01-01",{"name":135,"class":79},"University of Minnesota",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":109},"100617259","phase-3-pharmacologically-modulating-the-noradrenergic-arousal-system-to-reduce-freezing-of-gait-in-parkinsons-disease-a-multi-centre-and-multi-modal-approach-100617259","NCT07316296","Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach","AnTi-FREEZE","Inclusion Criteria:\n\n* Aged 18 years or older;\n* Diagnosis of idiopathic PD according to MDS Diagnostic Criteria;\n* Stabilised on optimal dopaminergic PD treatment for a minimum of four weeks prior to the baseline visit (Visit 1) and for the duration of the trial;\n* Presence of FOG symptoms on a daily basis;\n* Ability to walk for 10-meters unaided in the dopaminergic ON-state;\n* Ability to provide written informed consent in accordance with ICH-GCP and local regulations;\n* Willing and able to undergo all clinical trial assessments.\n\nExclusion Criteria:\n\n* Current and\u002For previous (within 3 months) participation in a clinical trial;\n* Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker);\n* Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments);\n* Severe cognitive impairment hampering the ability to comply with the study protocol;\n* Active psychosis that would impact the ability to comply with the study protocol;\n* Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc \\> 500ms Bazett-formula) and channelopathies that in the opinion of the study PI would significantly compromise participant safety;\n* Severe cerebrovascular disorders: cerebral aneurysm or recent\u002Fsignificant stroke;\n* Hepatic or renal insufficiency that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;\n* Narrow angle glaucoma;\n* (History of) pheochromocytoma;\n* Use of noradrenergic agents;\n* Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine);\n* Use of high dose salbutamol (or other beta2 agonists) that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;\n* Pregnancy and\u002For breastfeeding;\n* Known hypersensitivity to atomoxetine.",{"count":144,"type":21},60,[146],"PHASE3","The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is:\n\nDoes atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait?\n\nResearchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease.\n\nParticipants will:\n\nVisit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life",[149,28,32],"Parkinson's Disease (PD)","2026-02-24",{"date":152,"type":42},"2026-02-27",{"date":154,"type":42},"2026-01-01",{"date":156,"type":21},"2027-12-31",{"name":158,"class":79},"Radboud University Medical Center",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":89,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":109},"100564555","application-of-thoracic-epidural-scs-for-managing-fog-in-patients-with-advanced-parkinsons-disease-100564555","NCT06630702","Application of Thoracic Epidural SCS for Managing FOG in Patients With Advanced Parkinson's Disease","Application of Thoracic Epidural Spinal Cord Stimulation (SCS) for Managing Freezing of Gait (FOG) in Patients With Advanced Parkinson's Disease","Inclusion Criteria:\n\n* Age:40-85 years old.\n* Patients with primary Parkinson\\'s disease who have been diagnosed by a movement disorder specialist for more than 5 years. Although they have a clear response to drugs, they have a frozen gait that cannot be controlled by drugs. Lower limb pain may be present with or without Parkinson\\'s non-motor symptoms.\n* No other secondary gait problems.\n\nExclusion Criteria:\n\n* Atypical Parkinson's disease.\n* Patients with spinal cord injuries.\n* Medication-controlled frozen gait.\n* It is expected that there are lesions near the implantation area causing spinal canal stenosis or myelopathy (can be ruled out by MRI).\n* It is expected that the implantation area has undergone previous surgery or there is infection near the implantation area, which may affect the success rate of implantation or increase concerns about complications (such as severe extraspinal adhesion, or spinal cord damage in previous surgeries).\n* People with abnormal coagulation function (such as hemophilia patients) or those who have been controlled by long-term use of antithrombotic drugs and cannot stop taking them in a short period of time.\n* CDR (Clinical Dementia Rating Scale) ≧2. 8. Those who are allergic to developer.","40 Years",{"count":168,"type":21},5,[24],"Spinal cord stimulation (SCS) has proven to be effective for pain that is unresponsive to medication. This technique involves an anesthesiologist or a neurosurgeon placing stimulation electrodes at the thoracic vertebrae to provide pain relief. Although SCS is not currently a standard treatment for patients with Parkinson's disease, recent studies have shown that Parkinson's patients who experience intolerable pain and undergo SCS treatment not only experience pain relief but also show improvements in gait and other Parkinson's symptoms. Therefore, the investigators aim to use temporary, minimally invasive SCS electrodes to help patients with nrFOG (non-responsive Freezing of Gait) improve their stability and reduce their risk of falls.",[27,28,172],"Spinal Cord Stimulation",[174,27],"Spinal cord stimulation, Freezing of gait","2025-11-17",{"date":177,"type":42},"2025-11-20",{"date":179,"type":42},"2024-09-20",{"date":156,"type":21},{"name":182,"class":79},"National Taiwan University Hospital",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":89,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":109},"100454070","effect-of-theta-burst-transcranial-magnetic-stimulation-tbs-for-freezing-of-gait-100454070","NCT05192759","Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait","Inclusion Criteria:\n\n1. diagnosis of FOG with expertise in movement disorders.\n2. the score of item 3 of the FOG questionnaire ≥1.\n3. ongoing treatment with a stable dose of any medication for 2 months.\n4. 40 years of age or older.\n\nExclusion Criteria:\n\n1. a history of addiction, psychiatric disorders, or neurological diseases other than PD.\n2. focal brain lesions on T1-\u002FT2-weighted fluid-attenuated inversion recovery images.\n3. anti-PD medication adjustments during rTMS treatment.\n4. history of substance abuse within the past 6 months.\n5. nonremovable metal objects in or around the head.\n6. previously received rTMS treatment.\n7. prior history of seizure or history in first-degree relatives.",{"count":190,"type":21},40,[24],"To investigate the treatment effect of Theta-burst Transcranial Magnetic Stimulation (TBS) on patients with freezing of gait (FOG) and the underlying neural mechanism.",[194,28],"Transcranial Magnetic Stimulation",[194,196],"Freezing of gait",{"date":198,"type":42},"2025-11-19",{"date":200,"type":42},"2021-11-22",{"date":202,"type":21},"2028-12-30",{"name":204,"class":79},"Anhui Medical University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":109},"100589668","remote-mental-practice-for-freezing-of-gait-in-parkinsons-disease-100589668","NCT06957405","Remote Mental Practice for Freezing of Gait in Parkinson's Disease","Effects of a Remote Mental and Physical Practice Intervention on Freezing of Gait in People With Parkinson's Disease: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical diagnosis of idiopathic PD;\n* Use of dopaminergic medication;\n* Experiencing FOG (positive response to the first question of the New Freezing of Gait Questionnaire - NFOG-Q);\n* Able to walk independently at home;\n* Access to internet and video call device;\n* Agree to participate in the study.\n\nExclusion Criteria:\n\n* Other neurological disorders;\n* Severe cardiovascular and\u002For respiratory alterations;\n* Uncorrected visual and\u002For auditory alterations;\n* Cognitive impairment, detectable through the Telephone Montreal Cognitive Assessment (T-MoCA, \\\u003C 12);\n* Inability to perform motor imageryT during the administration of the Kinesthetic and Visual Imagery Questionnaire - 20 (KVIQ-20, \\\u003C 20)",{"count":213,"type":21},50,[24],"This single-blind, randomized controlled trial investigates the effects of a remotely delivered intervention based on mental practice (MP) combined with physical practice (PP) on freezing of gait (FOG) severity in people with idiopathic Parkinson's disease (PD). Fifty participants will be randomly assigned to either the experimental group (MP + PP) or a control group (PP + stretching). The intervention consists of 10 video-supervised sessions over 6 weeks. Primary outcomes include the Rapid Turn Test and percentage of time spent with FOG (%FOG). Secondary outcomes include the New Freezing of Gait Questionnaire (NFOG-Q), Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Questionnaire-39 (PDQ-39), and Telephone Montreal Cognitive Assessment (T-MoCA). The study aims to demonstrate whether MP using Dynamic Neuro-Cognitive Imagery (DNI) techniques can effectively reduce FOG severity and improve motor and cognitive function in people with PD.",[27,28],[126,28,218,219,220,221,33],"Mental Practice","Telerehabilitation","Dynamic Neuro-Cognitive Imagery","Motor Imagery","2025-08-20",{"date":224,"type":42},"2025-08-27",{"date":226,"type":42},"2025-01-25",{"date":228,"type":21},"2028-01",{"name":230,"class":79},"University of Sao Paulo General Hospital",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":18,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":109},"100577480","phase-2-spinal-cord-stimulation-for-freezing-of-gait-in-parkinsons-disease-100577480","NCT06798844","Spinal Cord Stimulation for Freezing of Gait in Parkinson's Disease","SCSforFOG","Inclusion Criteria:\n\n* Diagnosis of idiopathic PD in accordance with the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease\n* Optimal medical or DBS management for FOG, as evaluated by a movement disorder neurologist and programming expert. Stable PD medication and\u002For DBS settings for ≥ 1 month prior to baseline assessment and no changes are expected for the next 8 weeks\n* Self-reported FOG severity of ≥ 1 FOG episode per day, based on NFOG-Q items 1 and 2\n* Presence of FOG during in-hospital clinical assessment consisting of 3 FOG-provoking tasks, in the on-medication state\n* Able to walk 10 meters unassisted without a walking aid (use of a cane is allowed)\n* Able to understand study requirements and provide consent\n* Age 40-79 years inclusive\n\nExclusion Criteria:\n\n* Presence of other severe neurological, psychiatric or other disorder that may impede assessment of outcomes\n* Contra-indications to SCS surgery (e.g. epidural fibrosis, inability to safely discontinue anticoagulant drugs, allergy to implants, medically inoperable)\n* Cognitive impairment (Montreal Cognitive Assessment (MOCA) \\\u003C19\u002F30)\n* Chronic (\\>6m) severe (numeric rating scale \\>5\u002F10) back or leg pain, or FBSS, as the antalgic effect of SCS could cloud our interpretations for its effect on FOG\n* Duodopa pump or apomorphine injections\n* Fall frequency \\>1x\u002Fday (this criterion comprises only 'actual falls', no 'near falls')\n* Absence of FOG during preoperative at-home FOG-protocol, in on- or off-medication assessment\n* Pregnancy, lactating or active pregnancy plans",{"count":239,"type":21},29,[241],"PHASE2","Freezing of gait (FOG) is a severely disabling gait disorder in Parkinson's disease (PD). Its poor response to current therapies reflects the shortfall in current knowledge on its exact pathophysiology. Case series suggest a therapeutic promise of spinal cord stimulation (SCS) for FOG, but double-blind randomised controlled trials with reliable FOG assessments are lacking.\n\nThis randomised, double-blind, placebo-controlled cross-over trial aims to define the outcome, safety, optimal stimulation paradigm and underlying mechanism of SCS for FOG in PD, by exploring both clinical and neurophysiological parameters.\n\nTwenty-nine PD patients with refractory FOG will receive an implanted SCS lead connected to an external trial stimulator. During a 3-week trial, 3 stimulation paradigms will be tested in random order, including one sham paradigm. SCS outcome on FOG will be evaluated through wearable accelerometers, self-reported questionnaires and a FOG-provoking protocol at home. Spinal electrophysiological recordings will compare neural properties between PD patients with and without FOG and evaluate intra-patient differences (e.g., on\u002Foff medication, DBS states). In patients with deep brain stimulation (DBS) including BrainSense technology, the effect of SCS on pathological beta oscillations in the STN will be explored. A subsequent long-term open-label phase will be conducted in those patients who desire a definitive implanted stimulator.\n\nThis project will provide new insights into the pathophysiology of FOG, pave the way for SCS implementation in clinical practice and enhance future patient selection.",[28,27],[172,28,126],"2025-02-12",{"date":247,"type":42},"2025-02-13",{"date":249,"type":21},"2025-02",{"date":251,"type":21},"2028-12",{"name":253,"class":79},"Universitaire Ziekenhuizen KU Leuven",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":270,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100577974","phase-4-vortioxetine-for-depressive-symptoms-and-freezing-of-gait-in-parkinson-disease-100577974","NCT06805266","Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease","An Open Study to Evaluate the Efficacy of Vortioxetine on Freezing of Gait in Patients Affected by Parkinson Disease with Depressive Symptoms","Inclusion Criteria:\n\n1. Diagnosis of PD according to published criteria\n2. Occurrence of depression according to Beck Depression Inventory II (score ≥ 15)\n3. A score ≥ 2 on the freezing question #2.13 of part 2 of the MDS-UPDRS (moderate-severe FOG).\n4. FOG not responsive to dopaminergic treatment.\n\nExclusion Criteria:\n\n1. Treatment with IMAO-B (rasagiline, selegiline, safinamide) (to be included, IMAO-B need to be withdrawn for at least 15 days)\n2. Concomitant treatment with other antidepressant drugs\n3. Hepatic and renal insufficiency\n4. Treatment with tramadol or triptans\n5. Psychotic disorder\n6. Dementia according to DSM-V",{"count":190,"type":21},[263],"PHASE4","The present study involves patients with Parkinson Disease (PD) suffering from freezing of gait (FOG) and depressive symptoms. The main aim of the study is evaluating the efficacy of vortioxetine in reducing moderate\u002Fsevere FOG not responsive to dopaminergic treatment in patients with PD with depressive symptoms.",[66,28,266],"Depression Not Otherwise Specified",[27,268,269],"freezing of gait","depression NOS","NOT_YET_RECRUITING","2025-02-03",{"date":273,"type":42},"2025-02-06",{"date":249,"type":21},{"date":276,"type":21},"2027-02",{"name":278,"class":79},"Marianna Amboni",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":288,"conditions":289,"keywords":293,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":109},"100570901","study-of-the-link-between-freezing-of-gait-and-oropharyngeal-freezing-in-parkinsons-patients-100570901","NCT06713265","Study of the Link Between Freezing of Gait and Oropharyngeal Freezing in Parkinson's Patients","Freez in park","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease established by a neurologist;\n* Patient affiliated with the social security system;\n* Patient aged over 18 years.\n\nExclusion Criteria:\n\n* Patients under legal protection measures;\n* Neurological history that could be the cause of a swallowing disorder (e.g., stroke) or a history of ENT cancer;\n* Patient with a gastrostomy without oral intake;\n* Pregnant women or those suspected of being pregnant;\n* Minor patients",{"count":287,"type":21},66,"Parkinson's Disease: Study of the Link Between Gait Freezing and Oropharyngeal Freezing Parkinson's disease is the second most common neurodegenerative disorder worldwide. Parkinsonian dysphagia is a frequently encountered disorder in this condition, affecting all phases of swallowing: oral, pharyngeal, and esophageal. This dysphagia can occur at any stage of the disease. While most swallowing difficulties develop in the advanced stages of Parkinson's disease, they can also appear early on and are often underdiagnosed. The prevalence of swallowing disorders in Parkinson's disease is estimated to range from 40% to 80%, with this variability explained by the significant differences in the precision of swallowing evaluations conducted and the fact that dysphagia is still too frequently underdiagnosed. Yet, dysphagia is the leading cause of mortality in Parkinson's patients.\n\nDysphagia can negatively affect patients' quality of life. It leads to difficulties during oral intake (food, liquids, and medications), weight loss, dehydration, malnutrition, and limitations in social activities. Depression is frequently associated with reduced quality of life in Parkinson's patients with swallowing disorders. Moreover, aspiration pneumonia due to mis-swallowing is one of the primary reasons for hospitalization in Parkinson's patients, potentially leading to severe complications and, at times, death.\n\nOropharyngeal freezing, also called oral festination, is an involuntary, repetitive anteroposterior movement of the tongue against the soft palate performed before transferring the food bolus to the pharynx. This movement is also observed during multiple swallows. This phenomenon is more frequent in dysphagic Parkinson's patients, yet its impact on swallowing dynamics remains poorly understood. Oropharyngeal freezing has been observed in approximately 40% to 75% of Parkinson's patients during videofluoroscopic swallow studies, also known as swallowing pharyngography. Oropharyngeal freezing inhibits the initiation of swallowing, keeping the airway open and leading to tracheal aspiration of residues. Some fragments then slide into the valleculae and pyriform sinuses. Thus, oropharyngeal freezing exacerbates pharyngeal phase incoordination, increasing the risk of aspiration pneumonia. Therefore, addressing this swallowing disorder is essential.\n\nOropharyngeal freezing is intrinsically rhythmic. While limited studies have been conducted on the topic, they agree that gait freezing (difficulty initiating walking, stopping in response to obstacles, or circumventing them) and oropharyngeal freezing share common pathophysiological mechanisms. Gait freezing is not limited to deficits in the locomotor network but is part of a broader deficit affecting spatiotemporal coordination in various tasks, similar to oropharyngeal freezing.\n\nIt is, therefore, crucial to detect this oral phase swallowing disorder as early as possible, enabling tailored early intervention that helps patients maintain their swallowing abilities for as long as possible and prevents complications mentioned earlier. Since gait freezing is diagnosed much earlier and more systematically, it would be interesting to investigate whether there is a correlation between the presence of gait freezing and oropharyngeal freezing in these patients. This could guide patients with gait freezing toward early speech-language assessments to evaluate the presence of oropharyngeal freezing.\n\nThe objectives of the study are examine the prevalence of oropharyngeal freezing in Parkinson's patients. Based on the results obtained from the NFOG-Q (New Freezing of Gait Questionnaire), two groups will be formed: The first group will consist of patients exhibiting gait freezing. The second group will consist of patients without gait freezing. The secondary objectives of the study are examine the common characteristics between these two types of freezing (gait and oropharyngeal). To assess the sensitivity and reliability of the NFOG-Q in detecting oropharyngeal freezing.To determine the prevalence of oropharyngeal freezing based on the score obtained on the UPDRS (Unified Parkinson's Disease Rating Scale). To analyze the link between patients' rhythmic abilities and the presence or absence of one or both types of freezing.",[31,290,291,28,292,33],"Dysphagia","Swallowing Disorder","Oropharyngeal Disease",[294,290,295,196,296,297],"Parkinson's Disease","Swallowing disorder","oropharyngeal freezing","Gait","2024-12-02",{"date":300,"type":42},"2024-12-04",{"date":302,"type":42},"2024-10-04",{"date":304,"type":21},"2025-11-30",{"name":306,"class":79},"Hopital La Musse",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":18,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":109},"100540391","phase-4-dbs-and-levodopa-for-treating-freezing-of-gait-in-parkinsons-disease-100540391","NCT06316232","DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease","Efficacy of Deep Brain Stimulation and Levodopa on Freezing of Gait in Advanced Parkinson's Disease: a Comparative Study","Inclusion Criteria:\n\n* Patients with Parkinson's disease treated with STN-DBS who achieved a good control of motor fluctuations and cardinal motor symptoms (bradykinesia, rigidity, tremor)\n* History of FoG in daily-ON condition after optimal DBS programming, defined by a score of 1 on Question 1 and score ≥ 2 on Question 2 of the New Freezing of Gait Questionnaire.\n\nExclusion Criteria:\n\n* inability to walk independently for 10 meters.\n* limited therapeutic windows of stimulation without the possibility of increase the intensity of stimulation of 0,5 mA for the appearance of side effects\n* previous evidence of severe adverse effects with high levodopa dose ore increased STN-DBS intensity, such as psychosis, hallucinations, painful dyskinesias, severe hypotension, digestive symptoms.\n* dementia (MMSE score ≤ 18)",{"count":315,"type":21},20,[263],"Freezing of gait (FoG) is a complex symptom of Parkinson's disease (PD) that cause falls and disability in PD patients, heavily affect patients' autonomy and quality of life. Gait disturbances and FoG are difficult to manage as they usually do not complete respond to both dopaminergic treatment and subthalamic nucleus deep brain stimulation (STN-DBS). One therapeutic strategy suggested in literature for improving gait disturbances is to increase the dose of dopaminergic drugs according to the hypothesis of pseudo-ON-freezing. The pseudo-ON-FoG in patients treated with STN-DBS can easily occur as the result of a suboptimal stimulation or the consequence of a post-operative reduction of the dopaminergic therapy. Therefore, it is reasonable hypothesize both the increase of stimulation and levodopa as good therapeutic strategies to improve pseudo-ON-FoG. At present there are no evidence for suppose that one option is better than the other, even though two recent studies on gait analysis reported a positive additive effect of levodopa therapy on gait parameters in patients treated with STN-DBS.\n\nIn this study, the investigators aim to objectively evaluating the improvement of FoG in PD patients treated with STN-DBS at different treatment conditions consisting of increased intensity of stimulation or higher dosage of levodopa.",[28,27],[268,320,321],"gait disturbances","parkinson disease","2024-03-11",{"date":324,"type":42},"2024-03-18",{"date":326,"type":42},"2023-10-10",{"date":328,"type":21},"2026-12-31",{"name":330,"class":79},"IRCCS Istituto delle Scienze Neurologiche di Bologna"]